NASDAQ:ONC - Nasdaq - US07725L1026 - ADR - Currency: USD
236.86
+3.49 (+1.5%)
The current stock price of ONC is 236.86 USD. In the past month the price decreased by -6.29%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18 | 327.00B | ||
AMGN | AMGEN INC | 13.25 | 147.86B | ||
GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
NTRA | NATERA INC | N/A | 21.01B | ||
BIIB | BIOGEN INC | 8.25 | 19.13B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B | ||
UTHR | UNITED THERAPEUTICS CORP | 12.35 | 13.96B |
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
BEIGENE LTD-ADR
c/o Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay
George Town BEIJING KY
Employees: 11000
Phone: 13459494123
The current stock price of ONC is 236.86 USD. The price increased by 1.5% in the last trading session.
The exchange symbol of BEIGENE LTD-ADR is ONC and it is listed on the Nasdaq exchange.
ONC stock is listed on the Nasdaq exchange.
12 analysts have analysed ONC and the average price target is 258.74 USD. This implies a price increase of 9.24% is expected in the next year compared to the current price of 236.86. Check the BEIGENE LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BEIGENE LTD-ADR (ONC) has a market capitalization of 25.53B USD. This makes ONC a Large Cap stock.
BEIGENE LTD-ADR (ONC) currently has 11000 employees.
BEIGENE LTD-ADR (ONC) has a support level at 230.25 and a resistance level at 248.78. Check the full technical report for a detailed analysis of ONC support and resistance levels.
The Revenue of BEIGENE LTD-ADR (ONC) is expected to grow by 37.61% in the next year. Check the estimates tab for more information on the ONC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ONC does not pay a dividend.
BEIGENE LTD-ADR (ONC) will report earnings on 2025-08-05.
The PE ratio for BEIGENE LTD-ADR (ONC) is 5.89. This is based on the reported non-GAAP earnings per share of 40.2 and the current share price of 236.86 USD. Check the full fundamental report for a full analysis of the valuation metrics for ONC.
The outstanding short interest for BEIGENE LTD-ADR (ONC) is 26.08% of its float. Check the ownership tab for more information on the ONC short interest.
ChartMill assigns a technical rating of 1 / 10 to ONC.
ChartMill assigns a fundamental rating of 4 / 10 to ONC. ONC has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ONC reported a non-GAAP Earnings per Share(EPS) of 40.2. The EPS increased by 211.65% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -11.62% | ||
ROE | -20.59% | ||
Debt/Equity | 0.31 |
ChartMill assigns a Buy % Consensus number of 82% to ONC. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 109.55% and a revenue growth 37.61% for ONC